Nanomedicine Nanotechnology Biology and Medicine, Год журнала: 2025, Номер unknown, С. 102825 - 102825
Опубликована: Апрель 1, 2025
Язык: Английский
ESMO Open, Год журнала: 2025, Номер 10(2), С. 104084 - 104084
Опубликована: Янв. 7, 2025
Язык: Английский
Процитировано
2
Blood Reviews, Год журнала: 2025, Номер unknown, С. 101256 - 101256
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
1
Cancers, Год журнала: 2025, Номер 17(2), С. 282 - 282
Опубликована: Янв. 17, 2025
Chimeric antigen receptor T-cell (or CAR-T) therapy and bispecific antibodies (BsAbs) have revolutionized the treatment of hematologic malignancies, offering new options for relapsed or refractory cases. However, these therapies carry risks early complications, such as cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity (ICANS), delayed issues like graft-versus-host disease (GVHD), infections, secondary cancers. Effective management requires diagnosis using advanced biomarkers imaging, along with prompt interventions involving immunosuppressants, corticosteroids, inhibitors. A multidisciplinary approach is essential, integrating hematologists, oncologists, infectious specialists, emerging strategies targeted biologics personalized medicine showing promise in balancing efficacy toxicity management. Ongoing research critical to refine diagnostics treatments, ensuring that not only extend survival but also improve patients' quality life. This review provides insights healthcare professionals quickly recognize treat complications CAR-T BsAbs therapies. By focusing on detection through imaging outlining timely therapeutic interventions, it aims equip care team knowledge necessary manage challenges treatments effectively, ultimately optimizing patient outcomes.
Язык: Английский
Процитировано
1
Lymphatics, Год журнала: 2025, Номер 3(1), С. 2 - 2
Опубликована: Янв. 22, 2025
Multiple myeloma is an incurable hematologic malignancy arising from plasma cells. The uncontrolled growth of monoclonal cells leads to abnormal overproduction immunoglobulins. recommended course treatment for MM according disease progression and responses therapeutic intervention, highlighting the necessity multiple options that alleviate different parts MM. This comprehensive review provides insights into current treatments how take preventative prognostic measures. In advanced MM, osteoporosis a common symptom originates lack regulation in osteoclast activity bone resorption. Bisphosphonates such as zoledronic acid pamidronate along with antibodies denosumab hinder function aid reducing risk fractures patients For targeted therapy approaches, proteasome inhibitors impede protein degradation pathways cause accumulation misfolded proteins promoting cancer cell proliferation CAR-T another can utilize T target isolate Overall, this highlights frontrunners those diagnosed
Язык: Английский
Процитировано
1
Deleted Journal, Год журнала: 2025, Номер unknown
Опубликована: Янв. 16, 2025
Immuntherapien haben die Behandlung des multiplen Myeloms grundlegend verändert. Die Einführung von monoklonalen Antikörpern wie Daratumumab markierte einen ersten Durchbruch und etablierte diese Wirkstoffklasse in der Erstlinientherapie. Neuere Ansätze CAR-T-Zellen bispezifische Antikörper nutzen das enorme zytotoxische Potenzial T‑Zellen zur gezielten Eliminierung Krebszellen zeigen beeindruckende Ergebnisse. So ist Ciltacabtagen-Autoleucel (Cilta-Cel) bei Patienten mit Lenalidomid-refraktärer Erkrankung bereits ab zweiten Therapielinie zugelassen. Bispezifische bieten darüber hinaus auch nach CAR-T-Zell-Therapie vielversprechende Therapieoptionen. Besonders Aussicht, durch eine einmalige Infusion langanhaltende tiefe Remissionen zu erzielen, könnte Zukunft therapiefreien Intervallen für Patient:innen führen. Allerdings beinhalten neue Herausforderungen. Zum Beispiel wurde erhöhte Infektionsrate unter BCMA-adressierenden Therapien beobachtet, engmaschige Überwachung Substitution polyvalenten Immunglobulinen erfordert. Ebenso Antigenverlust ein potenzielles Problem, insbesondere sequenziellen berücksichtigt werden muss. Im vorliegenden Artikel Chancen, entstehen, erörtert gleichzeitig Herausforderungen Anforderungen, Therapieplanung sollten, angesprochen.
Процитировано
0
Expert Opinion on Biological Therapy, Год журнала: 2025, Номер unknown
Опубликована: Фев. 8, 2025
Introduction Bispecific antibody therapies, primarily targeting B-cell maturation antigen (BCMA), have shown remarkable outcomes in the treatment of heavily pretreated patients with multiple myeloma (MM). However, there are no current head-to-head trials informing practice for selection or sequencing optimal T cell redirection strategies later lines therapy. Linvoseltamab is a novel BCMA-targeted bispecific that was recently evaluated phase 1/2 LINKER-MM1 trial and currently pending formal regulatory approval.
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2025, Номер 17(4), С. 653 - 653
Опубликована: Фев. 14, 2025
Multiple myeloma (MM) is a complex and heterogeneous hematologic malignancy characterized by clonal evolution, genetic instability, interactions with supportive tumor microenvironment. These factors contribute to treatment resistance, disease progression, significant variability in clinical outcomes among patients. This review explores the mechanisms underlying MM including epigenetic changes that drive role of bone marrow microenvironment supporting growth immune evasion, impact genomic instability. We highlight critical insights gained from single-cell technologies, such as transcriptomics, genomics, multiomics, which have enabled detailed understanding heterogeneity at cellular level, facilitating identification rare cell populations drug resistance. Despite promise advanced remains an incurable challenges remain their application, high costs, data complexity, need for standardized bioinformatics ethical considerations. emphasizes importance continued research collaboration address these challenges, ultimately aiming enhance personalized strategies improve patient MM.
Язык: Английский
Процитировано
0
Advances in Radiation Oncology, Год журнала: 2025, Номер unknown, С. 101764 - 101764
Опубликована: Март 1, 2025
Proton therapy (PT) has distinct advantages in its ability to precisely target tumors while avoiding adjacent normal tissues. However, the distal edge effects of PT constrain application. This study investigated brain tissue response regions protons and compared it with effect photons. The occurrence damage from photons at was a murine model. Bragg peak treatment plans for models were optimized. Hematoxylin eosin immunofluorescence staining performed along margin. In addition, approximate distance neuronal sites calculated. Furthermore, small-molecule inhibitor studied inhibit microglia activation. injury model successfully established. Reactive gliosis granulovacuolar degeneration observed right hemisphere proton irradiation group. Neuronal injuries multiple locations (the frontal lobe, thalamus, cerebral cortex) border, but no injured neurons detected vertical photon exposed areas. Meanwhile, severe neural seen horizontal irradiation. At (0.4633 ± 0.01856 cm), abnormal morphology accumulated. IBA1 CD68 revealed activated corresponding sites, indicating their involvement irradiation-induced damage. Activated not irradiation, whereas many Moreover, asparagine endopeptidase inhibitors administered via intraperitoneal injection significantly reduced active thalamus cortex alleviated demonstrated that radiation induces accumulation edge. Targeting may play protective role radiation.
Язык: Английский
Процитировано
0
Medicine, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Advances in Clinical Medicine, Год журнала: 2025, Номер 15(04), С. 1122 - 1130
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0